JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Investing.com -- Niagen Bioscience Inc (NASDAQ:NAGE) stock rose 2% after the company announced an exclusive worldwide commercial license agreement with Norway’s Haukeland University Hospital to develop its nicotinamide riboside molecule as a potential Parkinson’s disease treatment.
The agreement grants Niagen Bioscience exclusive rights to proprietary intellectual property, know-how, and clinical data that is expected to support future regulatory filings for Parkinson’s disease therapy approval in the European Union. The license centers on data from the NOPARK trial, a phase III clinical study involving 400 individuals with early-stage Parkinson’s disease across 12 Norwegian sites.
The NOPARK study, which completed in June 2025, was a randomized, double-blind, placebo-controlled trial where participants received either 500 mg of nicotinamide riboside twice daily or placebo for 52 weeks. Results from this study are expected to be published by the end of 2025.
"This milestone underscores our long-term commitment to translating scientific innovation into meaningful therapeutic solutions," said Rob Fried, CEO of Niagen Bioscience.
The collaboration builds on a partnership dating back to March 2018 between Haukeland University Hospital’s Dr. Charalampos Tzoulis and Niagen Bioscience’s external research program. This partnership has supported four clinical trials assessing nicotinamide riboside’s therapeutic potential for Parkinson’s disease.
In connection with the license agreement, Niagen Bioscience has established a wholly owned subsidiary to support its transition from supplement science to regulated drug development for neurodegenerative diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.